,

Hone Health Announces US$228 Million to Expand Longevity Care

The package includes US$28 million in equity and US$200 million in growth financing as Hone expands beyond its original hormone-focused services.

Evidence Check
Company announcement. Hone disclosed the financing split and described where it plans to spend the money. The announcement provides no independent clinical evidence about the health outcomes of its services.

A clinician reviews a tablet beside sample tubes in a consultation room.

Hone Health announced US$228 million in financing to expand a business that began with hormone-focused care and now sells a broader range of physician-led services. The company says it will use the money to add clinical programmes, bring more diagnostic tests into its memberships and build technology that helps physicians review results over time.

How the package is structured

MarcyPen Capital Partners led a US$28 million Series A extension. A separate US$200 million in growth financing came from General Catalyst’s Customer Value Fund. Hone says it has raised US$65 million in equity to date. Its announcement did not give the terms of the growth financing.

The investment is aimed at expanding a care-delivery business, including the systems and staff that support it. A biotechnology financing round might fund laboratory work and human trials for a specific drug candidate. Hone plans to expand a membership platform spanning clinical consultations, testing and ongoing follow-up.

What Hone wants to build

Hone says it plans to expand physician-led programmes in metabolic health, inflammation and immunity. It also plans to add diagnostic options, including full-body MRI, DEXA scans, coronary CT angiography and gut microbiome testing, and collect results over time. Its upper-tier Hone Black membership is designed around extensive testing and ongoing care with a dedicated physician team, according to the company.

The company is developing software that uses artificial intelligence to organize lab results, symptoms, medication lists and medical history for physician review. That can give a clinician a more manageable view of information collected at different visits. Whether these tools improve decisions, reduce unnecessary follow-up or lead to better health outcomes would need to be tested. The company says it plans to build infrastructure for clinical trials, but it did not report results from those proposed studies in the financing announcement.

The deal shows how commercial longevity care can bring repeated biomarker testing, imaging and virtual consultations into a single subscription. The clinical value still depends on the test, the patient and the decision the result informs. A programme may collect more information at every visit while leaving open whether that information changes care in ways that improve patients’ lives.

Primary source: Hone Health financing announcement, November 18, 2026.

The Takeaway

Hone is using growth financing and equity to expand the way longevity services are packaged and delivered. As the business grows, its proposed research programme could help answer a practical question for patients and clinicians: which combinations of testing, follow-up and treatment produce better outcomes, for whom, and at what cost?